Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FNMXP
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,786
Award facts
- Contract value 100% obligated
- $3,785.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $3,785.80 firm fixed-price delivery order by the Defense Logistics Agency on September 22, 2025, for NUCALA 100 mg/mL syringes. The contract contains no set-aside designation and carries an ultimate completion date of September 23, 2025, with performance to be executed in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's significant single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products supporting medical supply needs across military health facilities.
NUCALA (mepolizumab) is a monoclonal antibody biologic medication used primarily for the treatment of eosinophilic asthma and other eosinophil-mediated conditions. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its IDC vehicle to provide direct distribution of prescription drugs and specialty medications to Department of Defense healthcare sites nationwide. The company's contract portfolio demonstrates consistent success in competing for federal pharmaceutical procurement without set-aside designations, supported by its woman-owned small business status and established presence as a federal contractor since 2001.
Quick answers
Who was awarded contract SPE2DB25FNMXP?
SPE2DB25FNMXP was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 22, 2025.
How much is contract SPE2DB25FNMXP worth?
The government has obligated $3,786 on SPE2DB25FNMXP.
Is contract SPE2DB25FNMXP an order under another contract?
Yes. SPE2DB25FNMXP is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB25FNMXP competed?
The extent of competition for SPE2DB25FNMXP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award